Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5EM04)

• Drug Name: CLL1-CD33 cCART cell therapy Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM5EM04

Molecule-Related Drug Atlas

Drug(s) Targeting Myeloid cell surface antigen CD33 (CD33)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gemtuzumab ozogamicin	DMJ2O7B	Acute myeloid leukaemia	2A60	Approved	[2]
Vadastuximab talirine	DM9LH10	Acute myeloid leukaemia	2A60	Phase 3	[3]
Actimab-A	DMKBIPR	Acute myeloid leukaemia	2A60	Phase 2	[3]
BI-836858	DMUVMY9	Myelodysplastic syndrome	2A37	Phase 2	[4]
Actimab-MDS	DMP8EEX	Myelodysplastic syndrome	2A37	Phase 2	[5]
GTB-3550	DMK2RIB	Acute myelogenous leukaemia	2A41	Phase 1/2	[6]
SGN-CD33A	DMRC7PI	Acute myeloid leukaemia	2A60	Phase 1/2	[7]
CART33 cells	DM81JIT	Myeloid leukaemia	2B33.1	Phase 1/2	[8]
CD33-specific gene-engineered T cells	DMM35D2	Acute myeloid leukaemia	2A60	Phase 1/2	[9]
Anti-CD33 CAR-T cells	DM9NPF6	Myeloid leukaemia	2B33.1	Phase 1/2	[10]

Drug(s) Targeting Myeloid inhibitory C-type lectin-like receptor (CD371)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CD123/CLL1 CAR-T Cells	DM45Z3P	Acute myeloid leukaemia	2A60	Phase 2/3	[11]
CLL1 CAR-T Cell	DMUOMBZ	Acute myeloid leukaemia	2A60	Phase 2/3	[11]
CLL1-specific gene-engineered T cells	DMCT917	Acute myeloid leukaemia	2A60	Phase 1/2	[9]
CAR-T cells targeting CLL1	DMCPM92	leukaemia	2A60-2B33	Phase 1/2	[12]
Tepoditamab	DMC84Y9	Acute myelogenous leukaemia	2A41	Phase 1	[13]
CLT030	DM674MP	Acute myeloid leukaemia	2A60	Phase 1	[14]
KITE-222	DMPF49Z	Acute myeloid leukaemia	2A60	Phase 1	[15]
UCART-CLL1	DMT06MI	Multiple myeloma	2A83	Preclinical	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Myeloid cell surface antigen CD33 (CD33)	TTJVYO3	CD33_HUMAN	Not Available	[1]
Myeloid inhibitory C-type lectin-like receptor (CD371)	TT70N8V	CL12A_HUMAN	Not Available	[1]

References

• [1] Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
• [2] Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging. 2009;4:197-205.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014 Jul;28(4):143-53.
• [5] Clinical pipeline report, company report or official report of Actinium Pharmaceuticals
• [6] Clinical pipeline report, company report or official report of GT Biopharma.
• [7] SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013 Aug 22;122(8):1455-63.
• [8] ClinicalTrials.gov (NCT01864902) Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
• [9] ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
• [10] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [11] ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
• [12] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [13] MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019 Jul;19(7):721-733.
• [14] Clinical pipeline report, company report or official report of Cellerant Therapeutics.
• [15] Clinical pipeline report, company report or official report of Gilead
• [16] Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199.